Danske Bank A/S
4.9.2026 14:37:30 CEST | Globenewswire | Press release
CORRECTION - Danske Bank A/S, transactions by persons discharging managerial responsibilities
CORRECTION - Danske Bank A/S, transactions by persons discharging managerial responsibilities
The original notification stated that 199,852 shares had been sold for a total of DKK 72,614,866.35. Danske Bank has subsequently received a revised notification confirming that 149,852 shares were sold for a total of DKK 54,494,866.35.
20 July 2026
Notification no. 55/2026
Transactions made by persons obliged to report transactions to the Danish FSA and Nasdaq Copenhagen, cf. the EU Market Abuse Regulation.
In connection with the share buy-back program in Danske Bank A/S, APMH Invest A/S continuously sells shares pro rata.
For further details, please find the attached templates for notifications and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.
Contact: Stefan Kailay Wind, Nordic Head of Media Relations, tel. +45 45 14 14 00
Attachment
Documents
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
SERB Pharmaceuticals23.10.2026 21:01:27 CEST | Press release
SERB Pharmaceuticals Announces Positive Results from the Post-Authorisation Efficacy Study of Idefirix® (imlifidase) Presented at ASN Kidney Week 2026
F. Hoffmann-La Roche Ltd23.10.2026 19:30:00 CEST | Press release
Roche presents interim phase III data showing sefaxersen significantly reduced proteinuria in people with IgA nephropathy (IgAN)
TecDo Technology Co., Limited23.10.2026 18:37:22 CEST | Press release
TGC 2026: Tec-Do Launches Navos Pro for Results-Driven AI for Work
CGTN23.10.2026 18:17:10 CEST | Pressemeddelelse
CGTN: Hvad fortæller historien om 'Half a Quilt' (Et halvt vattæppe) os om Kinas nye lange march?
Genmab A/S23.10.2026 17:55:00 CEST | Press release
Genmab Announces Rinatabart Sesutecan (Rina-S®) Demonstrates Statistically Significant Improvement in Progression-Free Survival and Overall Survival in Patients with Platinum-Resistant Ovarian Cancer
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom